Cholangitis Market Size and Share - Growth Analysis Report and Forecast Trends 2026-2030

Cholangitis refers to inflammation of the bile duct system, most commonly caused by bacterial infection, obstruction, or autoimmune disease, and the market encompasses diagnostics, therapeutics, and devices used in its management. Acute cholangitis is typically treated with antibiotics, biliary drainage, and supportive care, while chronic forms such as primary sclerosing cholangitis require long-term pharmacologic therapy and monitoring for progression to cirrhosis or cholangiocarcinoma. The market is moderately sized but expanding rapidly, reflecting both the growing burden of hepatobiliary disease worldwide and the entry of newer targeted therapies.

• •Global valuation around $1.24 billion in 2025.
• •Forecast CAGR of approximately 8.5% through 2035.
• •Acute cholangitis accounts for the largest share by disease type.

Rising incidence of gallstone-related obstruction, biliary strictures, and autoimmune liver disease is expanding the addressable patient population. Advances in endoscopic retrograde cholangiopancreatography (ERCP), MRCP imaging, and minimally invasive drainage devices are enabling earlier and more accurate intervention. Pharmaceutical innovation, particularly FXR agonists such as obeticholic acid and investigational agents like elafibranor, is creating new treatment lines for PSC, where unmet need has historically been high.

• •Aging populations and lifestyle factors are increasing gallstone and biliary disease prevalence.
• •Improved imaging and endoscopic technologies are boosting diagnosis rates.
• •Novel therapeutics for PSC are attracting significant R&D investment.

The market is segmented by disease type (acute, primary sclerosing, and secondary sclerosing cholangitis), by product (diagnostics, therapeutics, and devices), and by end user (hospitals, specialty clinics, and ambulatory surgical centers). North America currently leads in revenue, supported by established hepatology centers, high diagnosis rates, and reimbursement for advanced endoscopic procedures. Asia-Pacific is the fastest-growing region, driven by large patient pools, improving healthcare infrastructure, and increasing awareness in countries such as China, Japan, and India.

• •Therapeutics represent the largest and fastest-growing product segment.
• •Hospitals dominate end-user share due to the need for ERCP and inpatient care.
• •Asia-Pacific is projected to outpace North America and Europe in growth rate.

What are the recent trends and outlook?

Pipeline activity in PSC is intensifying, with FXR agonists, PPAR agonists, and bile acid transport inhibitors advancing through clinical trials, raising the prospect of the first approved disease-modifying therapy for PSC. Digital health tools and AI-assisted ERCP imaging are beginning to standardize diagnosis and procedural decision-making. Over the next decade, the market is expected to benefit from earlier diagnosis, broader use of combination therapy, and growing penetration in emerging regions, though high drug development costs and reimbursement uncertainty remain key constraints.

• •Multiple late-stage PSC drug candidates could reshape treatment standards by the early 2030s.
• •AI-enabled imaging is improving detection of biliary strictures and disease progression.
• •Long-term outlook remains strong, with double-digit expansion projected in emerging markets.